Immatics N : Corporate Presentation

Immatics

Corporate Presentation, July 2020

© 2020 Immatics. Not for further reproduction or distribution.

Forward Looking Statement

This presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.

Forward-Looking Statements. Certain statements in this presentation may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company's future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the IND filing for IMA204, IMA301, IMA401, the Company's focus on partnerships to advance its strategy, projections of future cash on hand and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company's filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Company undertakes no duty to update these forward-looking statements.

No Offer or Solicitation. This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company's own internal estimates and research. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source. This meeting and any information communicated at this meeting are strictly confidential and should not be discussed outside your organization.

2

Key Elements to Build a Global Leader in TCR-based Immunotherapies

Immatics' proprietary platforms create a leadership position in the TCR therapeutics space

• Two highly differentiated technology platforms for the discovery of pHLA targets & T cell receptors

• Foundation to achieve the next advance in immunotherapy, particularly for solid tumors

• Platforms validated by multiple strategic collaborations with oncology-focused global leaders incl. Amgen, Genmab, BMS, GSK and MD Anderson Cancer Center

Immatics is advancing a proprietary pipeline of Adoptive Cell Therapies (ACT) & TCR Bispecifics

• Four ACT programs in clinical development covering a broad range of solid cancers

• Two TCR Bispecifics programs with off-the-shelf availability in advanced preclinical development

• Next-Generationpersonalized multi-target approach designed to achieve durable clinical responses

Immatics builds on sustainable fundamentals

• Strong IP estate & worldwide rights retained on lead programs

• ~$253m proceeds from Arya/Immatics transaction July 2020 leading to $330m of cash on the balance sheet at the public debut and a cash runway of 3+ years

3

Making a Difference - Delivering the Power of T cells to Cancer Patients

Discovering Targets beyond the Cancer Cell Surface to Unlock Immunotherapies for Solid Cancers

CAR-T and Antibody-based

Approaches

• CAR-Tsuccessful in hematological indications but not in solid cancers
• Major limitation: targeting surface proteins on cancer cells, only constituting approx.
  25% of the proteome

TCR-based Approaches

• T cell receptors (TCRs) access intracellular targets displayed as peptides on cell surface through HLA receptors
• pHLA targets represent the entire proteome, an approx. 300% increased cancer target space vs. CAR-T and antibody-based approaches
• Immatics owns singular
  technologies to discover pHLA targets and TCRs to unlock immunotherapies for solid cancers

Adapted from Chandran et al., 2019

4

Proprietary Pipeline of Adoptive Cell Therapy (ACT) & TCR Bispecifics

Developing Novel Treatments Across Two Distinct Therapeutic Modalities

5

Recent Major Strategic Collaborations with World-leading Industry Players

Validation of Immatics' Unique Technologies and Expertise

2017

"Developing Novel Bispecific Cancer Immunotherapies"

2 Immatics targets

Immatics XPRESIDENT®, XCEPTOR™ and TCER™ technologies

$30m upfront

Focus on development of

Bispecifics

2018

"Next Generation Bispecific Cancer Immunotherapies"

3 Immatics targets

Immatics XPRESIDENT®, XCEPTOR™ and TCER™ technologies

$54m upfront

Focus on development of

Bispecifics

2019

"Strategic Collaboration to Develop Novel ACT"

3 Immatics targets

Immatics XPRESIDENT®, XCEPTOR™ and ACTengine® technologies

$75m upfront

Focus on development of Adoptive Cell Therapies

2020

"Strategic Collaboration to Develop Next-generation TCR Therapeutics"

2 Immatics targets

Immatics XPRESIDENT®, XCEPTOR™ and ACTengine® technologies

$50m upfront

Focus on development of Adoptive Cell Therapies

6

Immatics - Delivering the Power of T cells to Cancer Patients

IDENTIFY	DELIVER	PIONEER
True Targets	Therapeutic Pipelines	Multi-Target Personalized
and Right TCRs	of ACT and TCR Bispecifics	Precision Immunotherapy

Two Proprietary Technology Platforms	Two Distinct Modalities	Personalized & Precise
as foundation for the next advance	building a diverse	Product candidates against multiple individual
in immunotherapy,	preclinical and clinical pipeline	well characterized pHLA targets
particularly for solid tumors	Adoptive Cell Therapies	Proprietary XPRESIDENT®-AI
XPRESIDENT®	ACTengine® (TCR-T)	for full antigenic profiling and target selection
Target Discovery	ACTallo® (Next-generation)	of any individual tumor
>200 prioritized targets	TCR Bispecifics	Multi-Target/ TCR
XCEPTOR™	TCER™ - Off-the-shelf Biologics with
ACTolog® pilot study for multi-target ACT
TCR Discovery,	distinct attributes for use at	Building ACTengine® warehouse for
Engineering and Validation	an earlier disease stage	multi-targetTCR-T

7

Discovery of True Cancer Targets - XPRESIDENT® Technology Platform

Prioritization of >200 pHLA Targets Covering All Target Classes

pHLA DATABASE

based on primary tissues

Cancer tissues

20major

indications

&	>2,000 cancer & normal	>200
tissues analyzed by	prioritized
Normal tissues	Quantitative MS	targets
40tissue types
covering all
major organs

TARGET CLASSES

1. Well known and characterized parent protein e.g. MAGE family cancer testis antigens
2. Unknown or poorly characterized parent protein e.g. stroma target COL6A3 exon 6
3. Crypto-targets/Neoantigens:Novel target class which includes RNA-editedpeptides and non-classicalneoantigens

COMPETITIVE ADVANTAGES

• Leading LC-MS/MS based pHLA target discovery platform
• Discovery of most relevant naturally presented targets
• Ultra-sensitive(attomolar range) & quantitative (copy number per tumor cell)
• Extensive data set on normal tissues

8

Development of the Right TCR - XCEPTOR™ Technology Platform

Pioneering Novel Therapeutic Modalities: T cell Receptors (TCRs) for ACT and Bispecifics

Adoptive Cell Therapy			TCR Bispecifics
ACTengine®			T cell engaging
ACTallo®			receptor (TCER™)

	Proprietary XCEPTOR™ Platform
Natural or optimized natural TCR	TCR Discovery,
with micromolar affinity and	Engineering and Validation
favorable specificity profile	Fast and efficient discovery of
for genetic engineering of	multiple TCRs per target
autologous and allogeneic T cells	Unique XPRESIDENT®-guidedon-
and direct clinical application
	and off-target toxicity screening
	to deselect cross-reactive TCRs

Affinity-maturatednatural

TCR variable domains with nanomolar affinity and favorable specificity profile

XPRESIDENT®-guided

similar peptide counterselection

during maturation

Highly potent TCR Bispecifics format with

extended half-lifeand antibody-like

stability and manufacturability

9

Immatics - Delivering the Power of T cells to Cancer Patients

IDENTIFY	DELIVER	PIONEER
True Targets	Therapeutic Pipelines	Multi-Target Personalized
and Right TCRs	of ACT and TCR Bispecifics	Precision Immunotherapy

Two Proprietary Technology Platforms	Two Distinct Modalities	Personalized & Precise
as foundation for the next advance	building a diverse	Product candidates against multiple individual
in immunotherapy,	preclinical and clinical pipeline	well characterized pHLA targets
particularly for solid tumors	Adoptive Cell Therapies	Proprietary XPRESIDENT®-AI
XPRESIDENT®	ACTengine® (TCR-T)	for full antigenic profiling and target selection
Target Discovery	ACTallo® (Next-generation)	of any individual tumor
>200 prioritized targets	TCR Bispecifics	Multi-Target/ TCR
XCEPTOR™	TCER™ - Off-the-shelf Biologics with
ACTolog® pilot study for multi-target ACT
TCR Discovery,	distinct attributes for use at	Building ACTengine® warehouse for
Engineering and Validation	an earlier disease stage	multi-targetTCR-T

10

ACTengine® - Engineered TCR-T Therapy

Autologous, Genetically Modified T cells Expressing a Novel TCR

Lymphodepletion (Flu/ Cy)

T cell infusion Low dose IL-2

HLA-A*02

positive

Cancer patient

Biopsy: Biomarker profiling

ACTengine® IMA200 Series

Individual T cell product against selected target

Leukapheresis

x x x

4 Immatics targets

IMA201, 202, 203, 204

Genetic engineering

Approach

Study Design

• Proprietary TCR
• One target/ TCR per trial
• • Targets from ACTolog® warehouse
• 3 First-in-human trials ongoing (IMA201, IMA202, IMA203)
• Initial cohort with dose escalation: T cell dose increasing from 50x106 to 1,000x106 target-specific T cells/m²
• N=12-16patients per trial Expansion cohort upon clinical signal

Pre-activation

Transduction

Expansion

ACTengine® programs are supported by a grant of the Cancer Prevention & Research Institute of Texas (CPRIT)

11

pHLA Target Characteristics of Immatics' ACTengine® Lead Programs

Comparison of our Frontrunner Targets to Clinically Validated NY-ESO-1

Ongoing clinical ACTengine® trials

IND in 2021

	NY-ESO-15
Naturally presented	Yes1
Specificity class3	1
Copy number	10-504
Tumor types	Synovial sarcoma (80%)
Melanoma (40%)
with significant	HCC (40%)
prevalence	…

COL6A3 exon 6

IMA204

Yes2

2

100-7002

Pancreatic carcinoma (80%)

Breast carcinoma (75%) Stomach carcinoma (65%)

Sarcoma (65%)

Esophageal carcinoma (60%)

NSCLC (55%)

HNSCC (55%)

Uterine carcinosarcoma (55%) Colorectal carcinoma (45%)

Mesothelioma (45%)

Ovarian carcinoma (40%) Cholangiocarcinoma (40%)

Melanoma (35%)

Bladder carcinoma (35%)

…

Immatics' clinical frontrunner targets show specificity profiles similar to NY-ESO-1

while having significantly higher peptide copy numbers

1 Natural presentation of this peptide has been validated by clinical data, 2 Validated by XPRESIDENT® mass spectrometry. Target peptide copy numbers per cell were determined by AbsQuant™ technology, 3 Internal specificity categorization used at Immatics.

Specificity class 1: peptide not routinely found on any normal tissue; no relevant RNA expression detected on critical organs, Specificity class 2: peptide showing a large therapeutic window with rare detections on normal tissue and low RNA expression on critical organs. 12

4 Purbhoo et al., J Immunol 176:7308-7316 (2006), 5 Robbins et al., J Clin Onco 29(7): 917-924 (2011). Target prevalences for ACTengine® targets are based on TCGA data combined with a XPRESIDENT®-determined target individual MS-based mRNA expression threshold.

ACTengine® - Optimized Manufacturing

Established cGMP Capacities to Advance Next-Generation Cell Manufacturing Developments

Leukapheresis

Infusion-Ready

Manufacturing for ongoing ACT programs

• Proprietary short manufacturing process designed to produce phenotypically younger, better persisting T cells
• T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth, in Houston, TX
• 1,850 square foot state-of-the-artcGMP Facility operated by Immatics personnel
• Capacity: up to 48 manufacturing runs/month

13

ACTengine® - Initial Biological Data

Initial Data from IMA201, IMA202 and IMA203 as of 1Q 2020

Studies Enrollment Status

• Products successfully manufactured for 10/10 patients
• First 4 patients treated across IMA201, IMA202 and IMA203 trials at lowest dose of dose escalation scheme(50 million specific T cells/m²  5-10% of anticipated target dose at end of dose escalation)

Preliminary Biological Activity and Safety Data

• Very high frequencies of persisting circulating target-specific T cells observed at lowest infused dose (up to 45%)
• Current longest observation period is 12 weeks - during this time T cells persist
• Serial biopsy analysis demonstrates infiltration of target-specific T cells into post-treatment tumor biopsies
• ACTengine® treatment is well-tolerated to date with no changes to treatment regime required
• Next combined data read-out expected in 1Q 2021

Cellular Immunomonitoring in Blood

Molecular Immunomonitoring in Blood

Molecular Immunomonitoring in Tumor

IMA203 Patient #1

Vector copies/ug gDNA

1×106

1×105

1×104

1×103

1×102

1×101

1×100

201 Pt #1

202 Pt #1

203 Pt #1

202 Pt #2

IMA202 Patient #2, IMA203 Patient #1

IMA202 Pt#2

IMA203 Pt#1

Baseline	Day	1	3	1	2	3	4		8	12
						Week
		Day Week Week Week Week Week

Visit

January 2020

14

ACTallo® - Next Generation Off-the-shelfTCR-T Therapy

Allogenic, Genetically Modified γδ T cells Expressing a Novel TCR

Proprietary manufacturing expands

ACTallo® T cells rapidly to large numbers

HLA-A*02

positive

γδ T cells

• Are abundant in the peripheral blood
• Show intrinsic anti-tumor activity
• Naturally infiltrate solid tumors and correlate with favorable prognosis
• Are HLA-independent, thus do not cause GvHD in allogenic setting
• Can be expanded rapidly to high numbers in a cGMP-compliant manner
• Can be effectively redirected using αβ TCR or CAR constructs
• Are promising for an off-the-shelf cell therapy approach

15

TCER™ - Immatics' TCR Bispecifics

Mode of Action

16

TCER™ - Engineering an off-the-shelf Biologic

Adoptive Cell Therapy			TCR Bispecifics
ACTengine®			T cell engaging
ACTallo®			receptor (TCER™)

	Proprietary XCEPTOR™ Platform
Natural or optimized natural TCR	TCR Discovery,
with micromolar affinity and	Engineering and Validation
favorable specificity profile	Fast and efficient discovery of
for genetic engineering of	multiple TCRs per target
autologous and allogeneic T cells	Unique XPRESIDENT®-guidedon-
and direct clinical application
	and off-target toxicity screening
	to deselect cross-reactive TCRs

Affinity-maturatednatural

TCR variable domains with nanomolar affinity and favorable specificity profile

XPRESIDENT®-guided

similar peptide counterselection

during maturation

Highly potent TCR Bispecifics format with

extended half-lifeand antibody-like

stability and manufacturability

17

TCER™ - Summary IMA401 Lead Candidate

Proprietary TCR Bispecifics Format

• TCER™ design confers superior potency and stability compared to multiple tested alternative bispecific formats
• Significantly extended half life of several days as compared to competitor molecules

Very High Potency

• Very low concentration (low pM range) required for in vitro killing of tumor cells expressing physiological levels of target pHLA
• Complete tumor eradication in vivo (tumor xenograft mouse model)

Distinguished Specificity

• Broad therapeutic window (≥ 1,000 - 10,000 fold) as defined by reactivity against tumor cells and healthy tissue cells

Favorable CMC Characteristics

• Excellent manufacturability in CHO cells
• Very stable compound (stress testing in PBS)

Patient Population

• Target-positivesolid tumors, including cancers of the lung, head and neck, esophagus, sarcoma and several others

Tumor Xenograft Mouse Model

Study day -21: transplantation of tumor cells

Study day 0: human PBMC transplantation & start of treatment

18

Immatics - Delivering the Power of T cells to Cancer Patients

IDENTIFY	DELIVER	PIONEER
True Targets	Therapeutic Pipelines	Multi-Target Personalized
and Right TCRs	of ACT and TCR Bispecifics	Precision Immunotherapy

Two Proprietary Technology Platforms	Two Distinct Modalities	Personalized & Precise
as foundation for the next advance	building a diverse	Product candidates against multiple individual
in immunotherapy,	preclinical and clinical pipeline	well characterized pHLA targets
particularly for solid tumors	Adoptive Cell Therapies	Proprietary XPRESIDENT®-AI
XPRESIDENT®	ACTengine® (TCR-T)	for full antigenic profiling and target selection
Target Discovery	ACTallo® (Next-generation)	of any individual tumor
>200 prioritized targets	TCR Bispecifics	Multi-Target/ TCR
XCEPTOR™	TCER™ - Off-the-shelf Biologics with
ACTolog® pilot study for multi-target ACT
TCR Discovery,	distinct attributes for use at	Building ACTengine® warehouse for
Engineering and Validation	an earlier disease stage	multi-targetTCR-T

19

ACTolog® - Pioneering Personalized Multi-target T cell Therapy

Pilot Trial Using Autologous T cells Expressing Endogenous TCRs

Lymphodepletion (Flu/ Cy)

T cell infusion Low dose IL-2

Personalized multi-target T cell product against selected targets

HLA-A*02

positive

Cancer
Biopsy: Biomarker profiling
patient

x x x x

ACTolog® target warehouse

Leukapheresis

Selection of up to 4 targets

expressed on tumor

ACTolog® IMA101

Approach	• Personalized multi-target T cell therapy
using a warehouse approach
	• Autologous T cells, Endogenous TCRs
	• Clinical proof of concept previously
	delivered in melanoma by Cassian Yee
	(MD Anderson Cancer Center) with
	single target in combination with
	checkpoint inhibition [Chapuis et al., Sci
	Transl Med (2013) and Chapuis et al., JCO (2016)]

Indications • Basket trial in solid tumors

• First-in-humantrial ongoing

Study	• Cohort 1	(ACTolog® only)
Design/	•	Cohort 2	(plus Atezolizumab)
Status	•	Total of N=12 patients treated as of
		January 2020, up to N=20 planned

T cell manufacturing: priming and expansion

The ACTolog® program is supported by a grant of the Cancer Prevention & Research Institute of Texas (CPRIT)

20

ACTolog® - Pioneering Personalized Multi-target T cell Therapy

Preliminary Clinical Data as of January 2020

Patients

Feasibility

Biological Response

• 12 patients treated (various solid tumor indications).
• Median duration of disease of the patients was 4 years (range 2-18 years) with a median of 6 previous rounds of treatment (range 2-12).
• Very high ACTolog® cell doses (mostly >1010) could be administered.
• Patients received mostly multi-target ACTolog® products (range 1-3).
• ACTolog® has led to high target specific T cell levels and persistence with total frequencies up to 80% of all peripheral CD8+ T cells.
• T cells exhibit a non-exhausted phenotype.
• Target specific T cells were detectable in post-treatment tumor biopsies

Safety

Assessment

Preliminary

Clinical

Assessment

• ACTolog® IMA101 is well-tolerated to date with no changes to treatment regime required.
• The most common adverse events were expected cytopenias associated with the lymphodepleting regimen and Grade 1-2 cytokine release syndrome.
• Patients entered the trial with progressive disease, having failed the previous line of therapy.
• Median time to progression was ~12 weeks (range 6 weeks to 7 months) by RECIST1.1 (in some cases with transient tumor reduction of up to 26%).

21

Immatics' Multi-targetTCR-T Strategy and Vision

Addressing Major Challenges in Immuno-oncology to Make a Therapeutic Difference

1

2

3

4

ACTolog®

7 Immatics' targets

Screening completed

ACTengine®

IMA201-204

1 target/ TCR per trial

Trials recruiting

Initial ACTengine® warehouse

TCR combination trials

Multi-TCR warehouse

XPRESIDENT® Target Pool

IMA201-204 Warehouse

Extended Immatics TCR

Warehouse

Mission to treat every patient

ACTolog® = Multi-target Cell Therapy PILOT study

Delivered initial clinical data 2019

ACTengine® BLA filing(s)

for single TCR in specific indications (incl. niche)

Personalized Multi-targetTCR-TBLA filing of ACTengine® warehouse or single TCRs

e.g. IMA204 stroma targeting plus IMA201-203 tumor targeting

Single or Multi-target	Simultaneous targeting
TCR-T product	of tumor & stroma
Next generation efficacy	Overcoming tumor
heterogeneity and
enhancing technologies
tumor escape
(e.g. CD4 T cells, gene editing)
Overcoming the
Smart combination therapy	inhibitory tumor
microenvironment

22

The Leadership Team

Experienced Global Leadership Team Across Europe and the US

Harpreet Singh	Rainer Kramer
Chief Executive Officer	Chief Business Officer

Thomas Ulmer	Steffen Walter
Chief Financial Officer	Chief Technology Officer

Carsten Reinhardt	Cedrik Britten
Chief Development Officer	Chief Medical Officer

Toni Weinschenk	Jordan Silverstein
Chief Innovation Officer	Head of Strategy

23

Strong, Focused and Highly Integrated Trans-Atlantic Organization

United to Build a Global Leader in T cell Receptor-based Immunotherapies

Tübingen, Germany, 120 FTEs

Senior Leadership, Research and

Development (XPRESIDENT®,

XCEPTOR™, TCER™), Translational

Development, Clinical Operations,

Finance, HR, IT, QM

Munich, Germany, 10 FTEs

Houston, Texas , 70 FTEs

Senior Leadership, Research and

Development (Adoptive Cell Therapy),

CMC, Clinical Operations, Regulatory

Affairs, QA/QC, HR, Investor Relations

Senior Leadership, Business Development,

Intellectual Property, Regulatory Affairs,

Communications

24

Continuously Growing IP Portfolio Protecting Proprietary Know-How

Immatics' Patent Estate - Territorial Coverage

• ~ 5000 applications and patents

• >100 patent families

• IP protection on >8000 cancer targets, TCRs and technology
• Immatics files patent applications in all major countries and regions
• >230 granted patents in the US
• >15 granted patents in Europe
• >1550 granted patents overall

25

Immatics & ARYA Transaction Highlights

Transaction

Summary

Premier

Specialist

Investor Base

Use of

Proceeds

Key

Management

and Board

• The business combination transaction with Perceptive Advisors' sponsored SPAC - Arya Sciences Acquisition Corporation - was completed on July 1st, 2020
• The combined company, renamed Immatics N.V., starts trading its shares under the ticker symbol "IMTX" on the Nasdaq
• Proceeds from the transaction were approx. $250 million, combining funds held in Arya's trust account and a PIPE financing
• The shareholders of Arya and Immatics approved the transaction on June 29th, with no Arya shareholder redemptions
• Common shares outstanding: 63,383,750
• Immatics existing investor base (including dievini, AT Impf, Wellington Partners, MIG) continues to support the company
• The shareholder base will be extended by premier US investors including Perceptive Advisors, Redmile Group, Federated Hermes Kaufmann Funds, RTW Investments, Sphera Funds as well as previous SPAC shareholders
• A total of ~$253m including proceeds from the ~$104m PIPE financing as well as ~$149m Arya trust proceeds
• • Funding is expected to primarily be used for clinical programs and technology advancements, including ACTengine®, Next-Gen ACT and TCER™ technology
  • Funds are expected to provide runway into mid 2023
• Combined company is led by Immatics Chief Executive Officer, Harpreet Singh, Ph.D.
• Board of Directors is consisting of experienced executives from the life sciences sector

26

Milestones to Achieve the Next Advance in Immunotherapy

Immatics' Achievements to Date

• >200 prioritized targets
• Eight proprietary pipeline programs, four of them in clinical development
• ACT: Early clinical data obtained in 2019 demonstrating biological activity
• TCR Bispecifics: Manufacturing activities started for Lead Candidate
• Collaborations with global leaders in the field of immuno-oncology including GSK (2020),
  BMS (2019), Genmab (2018) & Amgen (2017)

Near-Term Value Inflection Points

Projected major value inflections 2020-2021 are expected to lead to a significant valuation step up

ACTengine®

• Next combined clinical data read-out for IMA201, 202 and 203 trials in 1Q 2021
• IND for IMA204 program in 2021

TCER™

• IND for the first TCER™ program IMA401, YE 2021
• Preclinical proof of concept for IMA402

Immatics brings together a breadth of technologies matched with deep knowledge of cancer-specific

targets and TCRs to advance the pipeline of Adoptive Cell Therapy and TCR Bispecifics.

27

Combining Key Elements to Become a Leading TCR Company

Proprietary	Foundation
Programs in	Development
Sustainable	Fundamentals

	2	>200		True targets	2		>1,550
Technology platforms			&
for the discovery of	prioritized cancer			Distinct Therapeutic	granted patents
targets		Right TCRs		Modalities
pHLA targets & TCRs			ACT & TCR Bispecifics
	4	2					10		Pioneering
ACT programs in clinical			development programs in	Next-gen Technologies
development	IND filings expected	collaborations with global		Novel Targets
industry leaders incl.
with data read-out expected in	in 2021			Off-the-shelf ACT
	GSK, BMS, Genmab,
	Multi-target personalized ACT
2020/early 2021					Amgen
							~$330m
>200	A fully integrated		>63m(1)
Employees	1,850 sq. ft.			IMTX		Cash
in Europe	cGMP site operational in	Shares outstanding
			No debt
& the US	Houston, TX

(1) plus ~7.2m warrants plus ~6.8m options	28

Thank you

www.immatics.com

Please contact us via [e-mail] to learn more about partnering and licensing opportunities utilizing our platform technologies XPRESIDENT®, XCEPTOR™, IMADetect™ and AbsQuant™. 29